38.56
0.06 (0.16%)
| Previous Close | 38.50 |
| Open | 38.53 |
| Volume | 2,082,220 |
| Avg. Volume (3M) | 1,366,966 |
| Market Cap | 2,991,087,616 |
| Price / Book | 9.52 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Diluted EPS (TTM) | -3.75 |
| Current Ratio (MRQ) | 26.48 |
| Operating Cash Flow (TTM) | -192.66 M |
| Levered Free Cash Flow (TTM) | -122.17 M |
| Return on Assets (TTM) | -35.87% |
| Return on Equity (TTM) | -56.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Mineralys Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.40% |
| % Held by Institutions | 103.83% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalys Pacific, Llc | 30 Jun 2025 | 8,903,838 |
| Sr One Capital Management, Lp | 30 Jun 2025 | 3,127,933 |
| Integral Health Asset Management, Llc | 30 Jun 2025 | 2,700,000 |
| Caligan Partners Lp | 30 Jun 2025 | 2,017,352 |
| Laurion Capital Management Lp | 30 Jun 2025 | 1,762,582 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Goldman Sachs, 34.86%) | Buy |
| Median | 43.00 (11.52%) | |
| Low | 26.00 (Jefferies, -32.57%) | Hold |
| Average | 42.60 (10.48%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 31.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 11 Sep 2025 | 50.00 (29.67%) | Buy | 37.33 |
| Goldman Sachs | 09 Sep 2025 | 52.00 (34.85%) | Buy | 38.50 |
| HC Wainwright & Co. | 08 Sep 2025 | 42.00 (8.92%) | Buy | 35.93 |
| 13 Aug 2025 | 42.00 (8.92%) | Buy | 13.56 | |
| Jefferies | 03 Sep 2025 | 26.00 (-32.57%) | Hold | 29.25 |
| B of A Securities | 28 Aug 2025 | 43.00 (11.51%) | Buy | 15.22 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |